Search

The performance of an Archimedes spiral turbine (AST) for hydrokinetic applications was examined using a three-dimensional unsteady numerical model utilizing the six degrees of freedom (6-DOF) solver that is available in ANSYs Fluent software. From the computational fluid dynamics (CFD) simulations, the power coefficient (Cp) curve was estimated. This curve was compared with the curve of an Archimedes screw hydrokinetic turbine (ASHT) reported in the literature. The ASHT was found to be more efficient than the AST for electricity generation. The highest value of Cp for the AST was 0.337, which is a relatively high value in comparison with that of other types of hydrokinetic turbines. The results calculated from the CFD for the AST were compared with an experimental study reported for wind applications. [ABSTRACT FROM AUTHOR]

Introduction: This scoping review explores the effectiveness of IL-1 pathway inhibitors in managing PSTPIP1-associated inflammatory diseases (PAID). These diseases are marked by abnormal IL-1 pathway activation due to genetic mutations. Methods: Our methodology adhered to a pre-published protocol and involved a thorough search of MEDLINE and EMBASE databases up to February 2022, following the Joanna Briggs Institute Reviewer's Manual and the PRISMA Extension for Scoping Reviews. The review included studies reporting on IL-1 pathway inhibitor use in PAID patients. Results: From an initial pool of 5,225 articles, 36 studies involving 43 patients were selected. The studies predominantly used observational designs and exhibited diversity in patient demographics, treatment approaches, and outcomes. Anakinra and canakinumab demonstrated promise in treating sterile pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) and PSTPIP1-associated myeloidrelated-proteinemia inflammatory (PAMI) syndromes, with scant data on other syndromes. Notably, there was a paucity of information on the adverse effects of these treatments, necessitating cautious interpretation of their safety profile. Conclusion: Current evidence on IL-1 pathway inhibitors for PAID is primarily from observational studies and remains limited. Rigorous research with larger patient cohorts is imperative for more definitive conclusions. Collaborative efforts among specialized research centers and international health initiatives are key to advancing this field. [ABSTRACT FROM AUTHOR]